Apgar; James M.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Apgar; James M..The latest application filed is for "tricyclic heterocycle compounds useful as hiv integrase inhibitors".

Company Profile

3.13.14

Apgar; James M. - Highland Park NJ
Apgar; James M. - Highland NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Tricyclic Heterocycle Compounds Useful As Hiv Integrase Inhibitors App 20210115044 - Yu; Tao ; et al.	2021-04-22
Substituted quinolizine derivatives useful as HIV integrase inhibitors Grant 10,786,488 - Yu , et al. September 29, 2	2020-09-29
Substituted Quinolizine Derivatives Useful As Hiv Integrase Inhibitors App 20190365727 - Yu; Tao ; et al.	2019-12-05
Nargenicin compounds and uses thereof as antibacterial agents Grant 10,144,741 - Young , et al. De	2018-12-04
Nargenicin Compounds And Uses Thereof As Antibacterial Agents App 20180186808 - Young; Katherine ; et al.	2018-07-05
Nargenicin compounds and uses thereof as antibacterial agents Grant 9,944,654 - Young , et al. April 17, 2	2018-04-17
Azabenzimidazole tetrahydrofuran derivatives Grant 9,868,733 - Apgar , et al. January 16, 2	2018-01-16
Nargenicin Compounds And Uses Thereof As Antibacterial Agents App 20170305924 - Young; Katherine ; et al.	2017-10-26
Benzimidazole hexahydrofuro[3,2-b]furan derivatives Grant 9,556,193 - Apgar , et al. January 31, 2	2017-01-31
Benzimidazole tetrahydrofuran derivatives Grant 9,540,364 - Apgar , et al. January 10, 2	2017-01-10
Benzimidazole tetrahydropyran derivatives Grant 9,527,839 - Apgar , et al. December 27, 2	2016-12-27
Azabenzimidazole tetrahydropyran derivatives Grant 9,382,243 - Apgar , et al. July 5, 2	2016-07-05
Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives Grant 9,290,517 - Apgar , et al. March 22, 2	2016-03-22
Novel Azabenzimidazole Hexahydrofuro[e,2-b]furan Derivatives App 20150284411 - Apgar; James M. ; et al.	2015-10-08
Novel Benzimidazole Tetrahydrofuran Derivatives App 20150218149 - Apgar; James M. ; et al.	2015-08-06
Novel Benzimidazole Hexahydrofuro[3,2-b]furan Derivatives App 20150218183 - Apgar; James M. ; et al.	2015-08-06
Novel Azabenzimidazole Tetrahydropyran Derivatives App 20150210685 - Apgar; James M. ; et al.	2015-07-30
Novel Azabenzimidazole Tetrahydrofuran Derivatives App 20150203487 - Apgar; James M. ; et al.	2015-07-23
Novel Benzimidazole Tetrahydropyran Derivatives App 20150197516 - Apgar; James M. ; et al.	2015-07-16
Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes Grant 8,853,212 - Wilkening , et al. October 7, 2	2014-10-07
Cyclic azabenzimidazole derivatives useful as anti-diabetic agents Grant 8,796,258 - Anand , et al. August 5, 2	2014-08-05
Novel Cyclic Azabenzimidazole Derivatives Useful As Anti-diabetic Agents App 20130123237 - Anand; Rajan ; et al.	2013-05-16
Substituted Aminotetrahydrothiopyrans And Derivatives Thereof As Dipeptidyl Peptidase-iv Inhibitors For The Treatment Of Diabetes App 20120277240 - Wilkening; Robert R. ; et al.	2012-11-01

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.